Therapeutic antibody production technologies: Molecules, applications, expression and purification

Current Opinion in Drug Discovery and Development

Volumn 4, Issue 2, 2001, Pages 172-185

  Humphreys, D P ^a   Glover, D J ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Antibody production; Downstream processing; Escherichia coli; Transgenic plants and animals; Yeast

Indexed keywords

ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; DRUG PURIFICATION; DRUG RESEARCH; ESCHERICHIA COLI; GLYCOSYLATION; PATENT; REVIEW; TRANSGENIC ANIMAL; TRANSGENIC PLANT; YEAST;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES; BIOTECHNOLOGY; CELL CULTURE TECHNIQUES; HUMANS; PLANTS, GENETICALLY MODIFIED; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0035073202     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (154)

1. Antibody engineering at the millennium
2. Antibody engineering and its applications in tumour targeting and intracellular immunization
3. Of mice and men: Hybridoma and recombinant antibodies
4. Clinical trials of antibody therapy
5. Human monoclonal antibodies specific to hepatitis B virus generated in a human/mouse radiation chimera: The Trimera system
6. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities
7. Antibody arrays for high-throughput screening of antibody-antigen interactions
8. The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies
9. Recombinant polyclonal antibody libraries
10. Single domain antibodies: Comparison of camel vH and camelised human vH domains
11. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies
12. Comparison of Escherichia coli and rabbit reticulocyte ribosome display systems
13. Development of an optimized expression system for the screening of antibody libraries displayed on the Escherichia coli surface
14. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides
15. Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries
16. A helper phage to improve single-chain antibody presentation in phage display
17. Selectively infective phage (SIP) technology: Scope and limitations
18. Directed evolution of a stable scaffold for T-cell receptor engineering
19. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies
20. High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice
21. Antibody humanization: A case of the 'Emperor's new clothes'?
22. Elimination of the immunogenicity of therapeutic antibodies
23. Human monoclonal antibodies: The emperor's new clothes?
24. Improving antibody affinity by mimicking somatic hypermutation in vitro
25. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues
26. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display
27. In vitro scanning saturation mutagenesis of an antibody binding pocket
28. In vitro scanning mutagenesis saturation of all the specificity determining residues in an antibody binding site
29. Immunotherapeutic perspectives for bispecific antibodies
30. High avidity scFv multimers; diabodies and triabodies
31. Generating improved single-chain Fv molecules for tumour targeting
32. Targeting of bivalent anti-ErB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity
33. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex
34. 1 in mice
35. 1 with hinge sequences conferring increased serum permanence times in an animal model
36. Catabolism of the murine IgG1 molecule: Evidence that both CH2-CH3 domain interfaces are required for persistence of IgG1 in the circulation of mice
37. Preparation of Fcγ for addition to sulfhydryl-expressing ligands with minimal disturbance of the hinge
38. Therapeutic antibody fragments with prolonged in vivo half-lives
39. The molecular weight ratio of monomethoxypolyethylene glycol (mPEG) to protein determines the immunotolerogenicity of mPEG proteins
40. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase
41. IgG-Fc-mediated effector functions: Molecular definition of interaction sites for effector ligands and the role of glycosylation
42. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity
43. Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins
44. Antibody targeted chemotherapy
45. Natural and engineered cytotoxic ribonucleases: Therapeutic potential
46. Eradication of large colon xenografts by targeted delivery of maytansinoids
47. In vitro folding and thermodynamic stability of an antibody fragment selected in vivo for high expression levels in Escherichia coli cytoplasm
48. Removal of the conserved disulfide bridges from the scFv fragment of an antibody: Effects on folding kinetics and aggregation
49. Selection for improved protein stability by phage display
50. Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen caspase-7
51. High level synthesis of immunoglobulins in Chinese hamster ovary cells
52. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker
53. Manufacture of therapeutic antibodies
54. Comparison of expression of a humanized monoclonal antibody in mouse NSO myeloma cells and Chinese hamster ovary cells
55. Construction of recombinant cell lines with defined properties using FLP recombinase driven gene replacement
56. Processing of transgenic corn seed and its effect on the recovery of recombinant β-glucuronidase
57. Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies
58. Production of a diagnostic monoclonal antibody in perennial alfalfa plants
59. Rapid production of single-chain Fv fragments in plants using a potato virus X episomal vector
60. Facile assessment of cDNA constructs for expression of functional antibodies in plants using the potato virus X vector
61. Structure, biosynthesis, and function of asparagine-linked glycans on plant glycoproteins
62. N-glycosylation of a mouse IgG expressed in transgenic tobacco plants
63. A murine monoclonal antibody produced in transgenic plants with plant-specific glycans is not immunogenic in mice
64. Transgenic milk as a method for the production of recombinant antibodies
65. Milking the genome for profit
66. Biopharmaceutical production in transgenic livestock
67. Species-specific variation in glycosylation of IgG: Evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics
68. High level Escherichia coli expression and production of a bivalent humanized antibody fragment
69. High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions
70. High level production of soluble single chain antibodies in small-scale Escherichia coli cultures
71. High-level periplasmic expression in Escherichia coli using a eukaryotic signal peptide: Importance of codon usage at the 5′ end of the coding sequence
72. The thioredoxin superfamily: Redundancy, specificity, and gray-area genomics
73. Protein folding in the bacterial periplasm
74. 1 fragments from Escherichia coli
75. The hierarchy of mutations influencing the folding of antibody domains in Escherichia coli
76. Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems
77. Selection for a periplasmic factor improving phage display and functional periplasmic expression
78. The periplasmic Escherichia coli peptidylprolyl cis,trans-isomerase FkpA. I. Increased functional expression of antibody fragments with and without cis-proline
79. The periplasmic Escherichia coli peptidylprolyl cis,trans-isomerase FkpA. II. Isomerase-dependent chaperone activity in vitro
80. 1 fragment from yeast cells
81. Increasing the secretory capacity of Saccharomyces cerevisiae for production of single-chain antibody fragments
82. High-level secretion of two antibody single chain Fv fragments by Pichia pastoris
83. Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: Expression, purification, and characterization
84. Overview of N- and O-linked oligosaccharide structures found in various yeast species
85. Expanded bed protein A affinity chromatography of a recombinant humanized monoclonal antibody: Process development, operation, and comparison with a packed bed method
86. Capture of human Fab fragments by expanded bed adsorption with a mixed mode adsorbent
87. Process intensification by direct product sequestration from batch fermentations: Application of a fluidised bed, multi-bed external loop contactor
88. Development of a mixed mode adsorption process for the direct product sequestration of an extracellular protease from microbial batch cultures
89. Recombinant production and purification of novel antisense antimicrobial peptide in Escherichia coli
90. Production in Escherichia coli of moricin, a novel type antibacterial peptide from the silkworm, Bombyx mori
91. Improved efficiency of site-specific copper(II) ion-catalyzed protein cleavage effected by mutagenesis of cleavage site
92. Utilizing the C-terminal cleavage activity of a protein splicing element to purify recombinant proteins in a single chromatographic step
93. Phage-displayed peptide libraries
94. Isolation of erythropoietin receptor agonist peptides using evolved phage libraries
95. Purification of monoclonal antibodies by epitope and mimotope affinity chromatography
96. Affinity chromatography on immobilized 'biomimetic' ligands. Synthesis, immobilization and chromatographic assessment of an immunoglobulin G-binding ligand
97. New strategy for the design of ligands for the purification of pharmaceutical proteins by affinity chromatography
98. Antibodies for the prevention and treatment of viral diseases
99. Antibody and virus: Binding and neutralization
100. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants
101. Therapeutic patents for topical and transdermal drug delivery systems
102. Transcutaneous immunization: A human vaccine delivery strategy using a patch
103. Induction of an HPV 6bL1-specific mucosal IgA response by DNA immunization
104. Mucosal vaccine delivery
105. Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells
106. Expansion of epitope cross-reactivity by anti-idiotype modulation of the primary humoral response
107. Immunological properties of a single-chain fragment of the anti-idiotype antibody ACA125
108. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies
109. Immunoglobulins and their contribution to defence mechanisms: An overview
110. Mucosal immunity - A major adaptive defence mechanism
111. 2: A possible implication for mucosal defense
112. In vitro comparison of the biologic activities of monoclonal monomeric IgA, polymeric IgA, and secretory IgA
113. Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes
114. Transmission of IgA and IgG monoclonal antibodies to mucosal fluids following intranasal or parenteral delivery
115. Recombinant expression of polymeric IgA: Incorporation of J chain and secretory component of human origin
116. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans
117. Generation and assembly of secretory antibodies in plants
118. Concepts and principles of O-linked glycosylation
119. O-glycosylation of a precursor to a sweet potato vacuolar protein, sporamin, expressed in tobacco cells
120. Isolation and characterization of the cDNA encoding a glycosylated accessory protein of pea chloroplast DNA polymerase
121. 1 and Fc regions and the role of N-glycosylation on Fcα receptor interactions
122. Structural requirements for incorporation of J chain into human IgM and IgA
123. Biogenesis and function of IgM: The role of the conserved μ-chain tailpiece glycans
124. Passive immunity against human pathogens using bovine antibodies
125. Comparison of an anti-HSV-2 monoclonal IgG and its IgA switch variant for topical immunoprotection of the mouse vagina
126. Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus
127. Long-term vaginal antibody delivery: Delivery systems and biodistribution
128. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments
129. Alternative triggering molecules and single chain bispecific antibodies
130. Complement recruitment using bispecific diabodies
131. Retargeting serum immunoglobulins with bispecific diabodies
132. 2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity
133. 2s): Engineering and expression of novel, dimeric molecules, with a molecular weight of 100 000
134. An efficient route to the production of an IgG-like bispecific antibody
135. High level secretion of a humanized bispecific diabody from Escherichia coli
136. Design and production of novel tetravalent bispecific antibodies
137. Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin γ1 Fc or CH3 region